Smart weaning from inhaled nitric oxide for newborns with PPHN
Part of Genetic & congenital, Lungs & breathing clinical trials.
This trial tests a new, smart way to slowly reduce (wean) the inhaled nitric oxide gas that helps babies with a serious lung condition called PPHN. If your baby is already responding well to iNO and needs it for at least 24 hours, this study might help make the weaning process safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby has started or is expected to start inhaled nitric oxide (iNO) for at least 24 hours due to a diagnosis of PPHN (a condition where blood vessels in the lungs tighten).
- Your baby has shown a clear improvement with iNO treatment.
- The iNO delivery machine used must be one that can be used with a smart closed-loop system to automatically adjust the gas flow.
- You or your child's legal guardian understand the study's risks and benefits and give written permission to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a portable device that delivers nitric oxide gas to help newborns with severe breathing problems and high blood pressure in the lungs. It aims to see if this treatment improves oxygen levels and supports recovery.
This study looks at whether an inhaled nitric oxide generator and delivery system can help newborns with high lung blood pressure (pulmonary hypertension). It may help improve oxygen levels during breathing support, but it requires specific medical eligibility and informed consent.
This trial tests whether inhaled nitric oxide gas can help full-term newborns who have severe breathing problems and high blood pressure in their lungs. It aims to improve oxygen levels and reduce the need for more intensive support.
This trial studies whether stopping inhaled nitric oxide (a breathing medicine) can be safely used in newborns with congenital diaphragmatic hernia (CDH). It may help the team decide the best way to use this medicine during early newborn care.
This trial tests whether giving a gas called inhaled nitric oxide helps newborns with a congenital diaphragmatic hernia breathe better and improve lung blood pressure. It's a type of treatment often used to help with lung problems in babies.
This study provides access to an experimental treatment called inhaled nitric oxide (delivered by the INOpulse device) for people with pulmonary hypertension caused by lung scarring. It aims to see if this treatment can help improve their condition.
Hear when a new Persistent Pulmonary Hypertension of the Newborn trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.